603259 (603259) News
Follow 603259 (603259) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 5 public stories across 4 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
WuXi AppTec faces requests from bondholders to convert bonds
WuXi AppTec said it is receiving further requests from certain bondholders to exercise conversion rights for its bonds.
EQUITY | Sep 21, 2026, 03:18 PM UTC
L
Long-Acting Oligonucleotide Development: Dosing, Yield and Stability Questions
San Diego, CA, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Longer-acting oligonucleotide medicines are attractive to drug developers because they can reduce dosing burden, improve treatment convenience, and potentially support be
RATES | Sep 10, 2026, 11:01 AM UTC
L
Oligonucleotide Drug Delivery Is Moving Beyond the Liver
San Diego, CA, Sept. 03, 2026 (GLOBE NEWSWIRE) -- For oligonucleotide medicines, precise delivery remains one of the field’s most important priorities. The liver has become an established target for systemic delivery, wi
EQUITY | Sep 03, 2026, 11:08 AM UTC
L
WuXi AppTec sells 53,524,000 shares of WuXi XDC via block trade
WuXi AppTec sold 53,524,000 shares in WuXi XDC via a block trade.
EQUITY | Aug 27, 2026, 10:50 PM UTC
M
Wuxi Apptec to dispose 53.5 mln shares in Wuxi XDC
Wuxi Apptec announced it will dispose 53.5 mln shares in Wuxi XDC via a block trade.
EQUITY | Aug 27, 2026, 01:47 PM UTC